Beta Bionics, Inc. (BBNX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$15.49-8.61%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · BBNX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -15.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 38.1% |
Growth built into the price is above our model estimate.
The price assumes 53.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
BBNX — debt issuance
Dated 2026-09-16
Other Events. On September 15, 2026, Beta Bionics, Inc. (the “Company,” “we,” “our” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co., Wells Fargo Securities, LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 7,652,175 shares of our common stock, par value $0.0001 per share. The…
Why it matters: Q3 gross margin was 57.3%, below the full-year range. The next results will show if the company can close that gap.
Supportive ifReported full-year 2026 gross margin is at least 58.5%.
Worry ifReported full-year 2026 gross margin is below 58.5%.
Why it matters: The pharmacy channel drove much of Q3 sales growth. Continued gains would support the company's channel expansion plan.
Supportive ifIn a later quarter, PBP net sales top $13.6 million, with year-over-year growth above 0%.
Worry ifA later quarter reports PBP net sales below $13.6 million.
Why it matters: The first application was withdrawn. New simulator data must support the revised filing before launch plans can move ahead.
Watch forBy mid-Q4 2026, the company submits a revised 510(k). It adds more simulator test data.
Also watch forThe revised filing is not submitted by mid-Q4 2026, or the FDA does not clear the algorithm.
Why it matters: Mint is cleared, but the full launch and planned output remain ahead. A timely launch can support new sales.
Supportive ifMint begins its U.S. launch in Q1 2027, and the company reports capacity for at least 1.5 million units that year.
Worry ifThe launch slips past Q1 2027 or planned 2027 capacity falls below 1.5 million units.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$268 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $749 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,230 loss on $10,000 · 72.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The pivotal trial is enrolled, but use in adults with type 2 diabetes still needs FDA clearance.
Supportive ifThe company reports a positive pivotal trial result. It seeks FDA clearance around mid-2027.
Worry ifThe trial misses its goal, or the planned mid-2027 clearance timing is delayed.